<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bishai, William R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Issues in the Management of MDR/XDR-TB</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">In 2008 Dr. Michael D. Iseman of National Jewish Health said, “In roughly 55 years we have squandered our precious legacy of chemotherapy for…tuberculosis [TB].” William R. Bishai, MD, PhD, Director of the The KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa, echoed this idea, saying that “HIV and multidrug- resistant [MDR] strains of TB threaten to reverse a half century of partial control of TB.” He was referring to the TB and HIV coepidemics in sub-Saharan Africa.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>